Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749909 | 0.85 | MAPT (0.56) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL1749907 | 0.85 | MAPT (0.56) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL4333368 | 0.81 | MAPT (0.52) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL1749646 | 0.80 | MAPT (0.57) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL3551387 | 0.80 | MAPT (0.57) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL1749644 | 0.80 | MAPT (0.57) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL2894910 | 0.80 | MAPT (0.43) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL3702193 | 0.79 | MAPT (0.56) | MAPTALDH1A1MAPK1POLBLMNA | |
| Hydrochloric Acid SCHEMBL5201475 | 0.79 | MAPT (0.56) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL7298691 | 0.79 | MAPT (0.62) | MAPTSIRT6MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213673-B1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8329711-B2 | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2213673-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE1, WEE2, CCNE1 | MAPT 4870/4885HSD11B1 2574/4885SIRT6 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.